"This is really a breakthrough in that we finally have something to treat these really difficult to treat patients." The FDA approved SGN-35 as a treatment for Hodgkin's Lymphoma in August 2011. It is the first FDA-approved Hodgkin's treatment since 1977. The drug is also used to treat other rare types of lymphoma such as t-cell non-Hodgkin's Lymphoma. The drug is mono-clonal antibody which attacks a protein on the surface of a lymphoma cell. It seeks out the cancer cell directly and spares the normal healthy cells. It is given through the vein once every three weeks. In some cases, SGN-35 can be used to get a patient ready to undergo a stem cell transplant. The Nebraska Medical Center and its education and research partner, the University of Nebraska Medical Center have been international leaders in lymphoma and leukemia treatment and research for decades, in many cases pioneering treatments used around the world. As one of the medical centers involved in the clinical trials of SGN-35, the medical center's team has experience with this new treatment. For more information about the hematology/oncology program at The Nebraska Medical Center, visit www.nebraskamed.com or call 1-800-922-0000.
Keywords: Nebraska, Medical, Center, cancer, oncology, hematology, lymphoma, cell, Hodgkins, Hodgkin's, non-hodgkin's, health, new, therapy, Pharmaceutical drug, Health care, doctor, Physician, pain, treatment, UNMC, cure, Omaha, t-cell, SGN-35, Brentuximab, vedotin, CD30, cd-30, SGN35, clinical, trial, seattle, genetics, medicine, patient, education, research, alternative, stem, bone, marrow, transplant, BMT, chemotherapy, protein, chemo, side, effects, affects
